5-hydroxy-3,7-diazanonane-1,9-dithiol | 840519-66-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-hydroxy-3,7-diazanonane-1,9-dithiol
• 英文别名: 1,3-Bis[(2-sulfanylethyl)amino]propan-2-ol；1,3-bis(2-sulfanylethylamino)propan-2-ol
• CAS: 840519-66-6
• 化学式: C₇H₁₈N₂OS₂
• 分子量: 210.365
• InChiKey: OKWABTJLMJPUFM-UHFFFAOYSA-N

物化性质

• 沸点：
  384.5±37.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.3
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-hydroxy-3,7-diazanonane-1,9-dithiol 、 17Beta-羟基-4-雄烯-3-酮 3-[邻羧基甲基]肟 在 三正丁胺 、 氯甲酸异丁酯 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  A novel 99mTc-labeled testosterone derivative as a potential agent for targeting androgen receptors

  摘要：

  With an insight that ligands possessing a N2S2 tetradentate array of donor atoms serve as ideal bifunctional chelating agents (BFCA) in the radiolabeling of target-specific agents, 5-hydroxy-3,7-diazanonan-1,9-dithiol (DAHPES) with a derivatizable substituent in the form of a hydroxyl group in the backbone was synthesized. The preparation of a steroid conjugate via coupling of this BFCA with testosterone-3-(O-carboxymethyl) oxime and the subsequent radiolabeling of the conjugate under optimized conditions with Tc-99m, the ideal diagnostic radionuclide in nuclear medicine procedures, are reported. The immunoreactivity of the radiolabeled conjugate was demonstrated in a study using anti-testosterone antibodies, wherein the radiolabeled conjugate exhibited significant binding with antiserum to testosterone. Cell-uptake studies in DU145 prostate carcinoma cell line bearing androgen receptors (ARs) and comparison with AR non-bearing breast carcinoma cell line revealed the specific binding of the steroidal moiety with the testosterone receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.081
• 作为产物：
  描述：

  环硫乙烷 、 1,3-二氨基-2-羟基丙烷 以 甲苯 为溶剂， 反应 40.0h， 以57%的产率得到5-hydroxy-3,7-diazanonane-1,9-dithiol
  参考文献：
  名称：

  A novel 99mTc-labeled testosterone derivative as a potential agent for targeting androgen receptors

  摘要：

  With an insight that ligands possessing a N2S2 tetradentate array of donor atoms serve as ideal bifunctional chelating agents (BFCA) in the radiolabeling of target-specific agents, 5-hydroxy-3,7-diazanonan-1,9-dithiol (DAHPES) with a derivatizable substituent in the form of a hydroxyl group in the backbone was synthesized. The preparation of a steroid conjugate via coupling of this BFCA with testosterone-3-(O-carboxymethyl) oxime and the subsequent radiolabeling of the conjugate under optimized conditions with Tc-99m, the ideal diagnostic radionuclide in nuclear medicine procedures, are reported. The immunoreactivity of the radiolabeled conjugate was demonstrated in a study using anti-testosterone antibodies, wherein the radiolabeled conjugate exhibited significant binding with antiserum to testosterone. Cell-uptake studies in DU145 prostate carcinoma cell line bearing androgen receptors (ARs) and comparison with AR non-bearing breast carcinoma cell line revealed the specific binding of the steroidal moiety with the testosterone receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.081

文献信息

• A novel 99mTc-labeled testosterone derivative as a potential agent for targeting androgen receptors
  作者：Tapas Das、Sharmila Banerjee、Grace Samuel、Ketaki Bapat、Suresh Subramanian、Maroor R.A. Pillai、Meera Venkatesh

  DOI：10.1016/j.bmcl.2006.08.081

  日期：2006.11

  With an insight that ligands possessing a N2S2 tetradentate array of donor atoms serve as ideal bifunctional chelating agents (BFCA) in the radiolabeling of target-specific agents, 5-hydroxy-3,7-diazanonan-1,9-dithiol (DAHPES) with a derivatizable substituent in the form of a hydroxyl group in the backbone was synthesized. The preparation of a steroid conjugate via coupling of this BFCA with testosterone-3-(O-carboxymethyl) oxime and the subsequent radiolabeling of the conjugate under optimized conditions with Tc-99m, the ideal diagnostic radionuclide in nuclear medicine procedures, are reported. The immunoreactivity of the radiolabeled conjugate was demonstrated in a study using anti-testosterone antibodies, wherein the radiolabeled conjugate exhibited significant binding with antiserum to testosterone. Cell-uptake studies in DU145 prostate carcinoma cell line bearing androgen receptors (ARs) and comparison with AR non-bearing breast carcinoma cell line revealed the specific binding of the steroidal moiety with the testosterone receptor. (c) 2006 Elsevier Ltd. All rights reserved.